Glaxo Lacks Diversified Drug Portfolio: Rundquist

July 24 (Bloomberg) -- Odile Rundquist, senior analyst at Helvea, previews quarterly results from Glaxo Smithkline, looks at the impact of the drugmaker's recent troubles in China and compares the U.S. and European pharma sectors. She speaks on Bloomberg Television's "On The Move."

SNB Has Nuclear Option to Negative ECB Rates: Barth
26:38 - Marvin Barth, head of European FX strategy at Barclays, talks about the impact on currencies from the economic divergence in the U.S. and Europe and the key role to be played by the Swiss National Bank. He speaks on "Bloomberg Surveillance." (Source: Bloomberg)
  • What to Watch for in U.K.'s Autumn Statement
  • What Putin’s ‘Serious Consequences’ May Mean for Turkey
  • Are Emerging Markets Prepared for ECB, Fed Moves?